The candidate research focuses on understanding the mechanisms of hematopoietic cell transformation, clonal evolution, and resistance using a combination of genomics and functional studies. The candidate has a strong track-record in genomics with several high impact papers and she had a leading role in The Pediatric Cancer Genome Project (Nature Genetics, 2015, cited 501). In 2012, she returned to Lund, to start a highly competitive research program with a strong focus on genomics.
Anna Hagström
Lund University
Keywords
Key Publications
The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia
Nature Communications, 2025
Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in <i>KMT2A</i>-rearranged acute leukemia.
HemaSphere, 2024
Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture-Based Gene Panel.
Genes, chromosomes & cancer, 2024
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.
Genome biology, 2024
SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia.
Scientific reports, 2024